Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims Global News Select Sep 27, 2024, 3:48:00 AM ...

Review Cassava Sciences Inc (SAVA:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, which ...

Cassava's Earnings Overview Yesterday, on August 8th, Cassava Sciences reported its Q2 2024 financial results, showing a net income of $6.2 million, a significant turnaround from the $26.4 million ...

Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.